CTLA4 and neoplasm: Importantly, CTLA-4 blockade monotherapy upregulated the expression of CSF-1R in tumor-infiltrating MDSCs and inhibited T cell proliferation, whereas anti-CSF-1R and CTLA-4 blockade combined treatment induced antitumor T-cell responses and tumor regression in multiple tumor models [144].